Clinico-biological refinement of BCL11B-related disorder and identification of an episignature: A series of 20 unreported individuals

Quentin Sabbagh,Sadegheh Haghshenas,Juliette Piard,Chloé Trouvé,Jeanne Amiel,Tania Attié-Bitach,Tugce Balci,Mouna Barat-Houari,Alyce Belonis,Odile Boute,Diana S Brightman,Ange-Line Bruel,Stefano Giuseppe Caraffi,Nicolas Chatron,Corinne Collet,William Dufour,Patrick Edery,Chin-To Fong,Carlo Fusco,Vincent Gatinois,Evan Gouy,Anne-Marie Guerrot,Solveig Heide,Aakash Joshi,Natalya Karp,Boris Keren,Marion Lesieur-Sebellin,Jonathan Levy,Michael A Levy,Claire Lozano,Stanislas Lyonnet,Henri Margot,Pauline Marzin,Haley McConkey,Vincent Michaud,Gaël Nicolas,Mevyn Nizard,Alix Paulet,Francesca Peluso,Vincent Pernin,Laurence Perrin,Christophe Philippe,Chitra Prasad,Madhavi Prasad,Raissa Relator,Marlène Rio,Sophie Rondeau,Valentin Ruault,Nathalie Ruiz-Pallares,Elodie Sanchez,Debbie Shears,Victoria Mok Siu,Arthur Sorlin,Matthew Tedder,Mylène Tharreau,Frédéric Tran Mau-Them,Liselot van der Laan,Julien Van Gils,Alain Verloes,Sandra Whalen,Marjolaine Willems,Kévin Yauy,Roberta Zuntini,Jennifer Kerkhof,Bekim Sadikovic,David Geneviève,Diana S. Brightman,Michael A. Levy

DOI: https://doi.org/10.1016/j.gim.2023.101007

IF: 8.864

2024-01-01

Genetics in Medicine

Abstract:PURPOSE: BCL11B-related disorder (BCL11B-RD) arises from rare genetic variants within the BCL11B gene, resulting in a distinctive clinical spectrum encompassing syndromic neurodevelopmental disorder, with or without intellectual disability, associated with facial features and impaired immune function. This study presents an in-depth clinico-biological analysis of 20 newly reported individuals with BCL11B-RD, coupled with a characterization of genome-wide DNA methylation patterns of this genetic condition.METHODS: Through an international collaboration, clinical and molecular data from 20 individuals were systematically gathered, and a comparative analysis was conducted between this series and existing literature. We further scrutinized peripheral blood DNA methylation profile of individuals with BCL11B-RD, contrasting them with healthy controls and other neurodevelopmental disorders marked by established episignature.RESULTS: Our findings unveil rarely documented clinical manifestations, notably including Rubinstein-Taybi-like facial features, craniosynostosis, and autoimmune disorders, all manifesting within the realm of BCL11B-RD. We refine the intricacies of T cell compartment alterations of BCL11B-RD, revealing decreased levels naive CD4⁺ T cells and recent thymic emigrants while concurrently observing an elevated proportion of effector-memory expressing CD45RA CD8⁺ T cells (TEMRA). Finally, a distinct DNA methylation episignature exclusive to BCL11B-RD is unveiled.CONCLUSION: This study serves to enrich our comprehension of the clinico-biological landscape of BCL11B-RD, potentially furnishing a more precise framework for diagnosis and follow-up of individuals carrying pathogenic BCL11B variant. Moreover, the identification of a unique DNA methylation episignature offers a valuable diagnosis tool for BCL11B-RD, thereby facilitating routine clinical practice by empowering physicians to reevaluate variants of uncertain significance within the BCL11B gene.

genetics & heredity